Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
暂无分享,去创建一个
Sung-Bae Kim | M. Shah | P. Enzinger | K. Muro | Chih-Hung Hsu | L. Shen | Se-Hoon Lee | Ken Kato | J. Metges | S. Qin | A. Adenis | T. Doi | T. Kojima | T. Moriwaki | J. Bennouna | E. François | Rui-xue Wang | P. Ferreira | P. Bhagia | S. Kang